Key facts
- It has raised $18.9M; the latest was Accelerator/Incubator in May 2025.
- Notable investors include EIT Food, Innovation Authority, Seeds of Bravery, Alpha Capital Anstalt, Galil Ofek Innovation — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for BioBetter
- ·The full record, as it builds
Funding rounds
No funding rounds for BioBetter are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioBetter
Developer of an agri-tech platform designed to simplify protein manufacturing and purification of biological drugs. The company's platform focuses on refining and emphasizing the inherent advantages of plants as bioreactors for protein expression using transgenic plants that co-express target therapeutic proteins together with enzymes that remove antigenic sugars from the target protein, enabling biotech professionals to reduce the cost of protein manufacturing.
- Sector
- Healthcare
- HQ
- Tel-Hai, Israel
- Founded
- 2015
- Employees
- 45
- Website
- biobetter.bio/
- Ownership
- Privately Held (backing)
BioBetter doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioBetter shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioBetter in its N-PORT filings yet. We sweep new filings monthly.